Bulgaria vs Equatorial Guinea: The number of people with susceptibility test result for rifampicin
Bulgaria
47.71
in 2021
Equatorial Guinea
54.36
in 2021
Bulgaria rank
115th
Equatorial Guinea rank
113th
The number of people with susceptibility test result for rifampicin over time
- Bulgaria
- Equatorial Guinea
How they compare
Equatorial Guinea currently reports 54.36 against 47.71 in Bulgaria, a difference of 6.65.
That makes Equatorial Guinea's figure about 1.1 times Bulgaria's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Bulgaria ahead.
Bulgaria ranks 115th and Equatorial Guinea ranks 113th of 146 countries.
Bulgaria has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bulgaria | Equatorial Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 80.4 | 4.02 | 76.38 | Bulgaria |
| 2020s | 49.92 | 42.43 | 7.5 | Bulgaria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Bulgaria or Equatorial Guinea?
- Equatorial Guinea, at 54.36 against 47.71 in Bulgaria as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Bulgaria and Equatorial Guinea?
- 6.65, with Equatorial Guinea ahead.
- How many years of comparable data are there for Bulgaria and Equatorial Guinea?
- 5 years are reported by both, from 2017 to 2021.
- How do Bulgaria and Equatorial Guinea rank globally for the number of people with susceptibility test result for rifampicin?
- Bulgaria ranks 115th and Equatorial Guinea ranks 113th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.